drugset
drugset / Trial / NCT00225615

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

NCT00225615 ↗

Phase 3 Completed 100 enrolled BioMarin Pharmaceutical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.

Timeline

Start
2005-11
Primary completion
—
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject sapropterin Unknown — —

Indications

phenylketonuria